Physician profile
Douglas Scott Eddy
NPI 1982961124
$8,924.09
in general payments reported to CMS, 2019-2025
46 companies · $1,740 in 2025
The $1,740 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,751 · 2020: $698 · 2021: $930 · 2022: $392 · 2023: $1,361 · 2024: $2,053 · 2025: $1,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,153.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,269.90 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $1,137.21 | 2019-2025 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $755.87 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $674.36 | 2019-2024 | Trelegy Ellipta, Benlysta, Arexvy |
| Pfizer INC. | $556.77 | 2019-2025 | |
| Lilly USA, LLC | $414.18 | 2019-2025 | Mounjaro, Zepbound, Taltz |
| Novo Nordisk INC | $411.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $361.78 | 2022-2025 | Freestyle Libre, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $322.40 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.21 | 2019-2025 | Ofev, Jardiance, Cyltezo |
| Ucb, INC. | $298.38 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $293.62 | 2019-2021 | |
| Astellas Pharma US INC | $196.83 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $145.76 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $144.25 | 2024-2025 | Gemtesa |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Eddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.